Price T Rowe Associates Inc Fulcrum Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 52,368 shares of FULC stock, worth $193,237. This represents 0.0% of its overall portfolio holdings.
Number of Shares
52,368
Previous 35,712
46.64%
Holding current value
$193,237
Previous $128,000
92.97%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding FULC
# of Institutions
134Shares Held
52.8MCall Options Held
3.08MPut Options Held
316K-
Ra Capital Management, L.P. Boston, MA10.2MShares$37.7 Million0.78% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.25MShares$19.4 Million4.03% of portfolio
-
Black Rock Inc. New York, NY4.8MShares$17.7 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT4.78MShares$17.6 Million1.13% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.34MShares$12.3 Million0.65% of portfolio
About Fulcrum Therapeutics, Inc.
- Ticker FULC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,038,900
- Market Cap $192M
- Description
- Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...